AOH1996 for relapsed or refractory acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, AOH1996, for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if this drug is safe and helps control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have AML that has returned or not responded to previous treatments, and there are no other standard treatments available or you can't take them.
- You need to be able to swallow pills.
- Your liver and kidney function must be within certain limits.
- You must not have had a stem cell transplant in the last 100 days or certain other cancer treatments in the last 14 days.
- You must not have certain heart conditions or other serious uncontrolled health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
This early-stage (Phase 1) trial tests AOH1996 in adults with solid tumors that have stopped responding to standard treatments. It’s meant to find a safe dose and see if the drug can help, especially in cancers with limited options.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This trial tests a new drug called APL-4098, given alone or with another medicine, for people with certain blood cancers (AML or MDS) that have come back or not responded to treatment. The goal is to see if it is safe and works well.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
Hear when a new Recurrent Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.